These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

777 related items for PubMed ID: 33067320

  • 1. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
    Ghosh N, Tirpack A, Chan KK, Bass AR.
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320
    [Abstract] [Full Text] [Related]

  • 2. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
    Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Cartenì G, Cavallero D, Cavo A, Ciardiello F, Conca R, Conteduca V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, Messina C, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, Pagliuca M, Palmieri G, Parola S, Pepe S, Petrillo A, Piantedosi F, Piccin L, Picozzi F, Pietroluongo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, Zivi A, Daniele B, Ascierto PA, SCITO (Società Campana di ImmunoTerapia Oncologica).
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060148
    [Abstract] [Full Text] [Related]

  • 3. Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.
    Maio M, Hamid O, Larkin J, Covre A, Altomonte M, Calabrò L, Vardhana SA, Robert C, Ibrahim R, Anichini A, Wolchok JD, Giacomo AMD.
    Clin Cancer Res; 2020 Aug 15; 26(16):4201-4205. PubMed ID: 32540850
    [Abstract] [Full Text] [Related]

  • 4. ICI Impact on COVID-19 Severity Modest at Best.
    Cancer Discov; 2020 Oct 15; 10(10):1432-1433. PubMed ID: 32816844
    [Abstract] [Full Text] [Related]

  • 5. Immunotherapy is a preferred option for oral cancer patients during COVID-19 pandemic?
    Chu C, Sun Y, Pan Y.
    Oral Oncol; 2020 Aug 15; 107():104860. PubMed ID: 32571643
    [No Abstract] [Full Text] [Related]

  • 6. Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment.
    Rossi E, Schinzari G, Tortora G.
    J Immunother Cancer; 2020 Jul 15; 8(2):. PubMed ID: 32699182
    [Abstract] [Full Text] [Related]

  • 7. Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.
    Ürün Y, Hussain SA, Bakouny Z, Castellano D, Kılıçkap S, Morgan G, Mckay RR, Pels K, Schmidt A, Doroshow DB, Schütz F, Albiges L, Lopes G, Catto JWF, Peters S, Choueiri TK.
    JCO Glob Oncol; 2020 Aug 15; 6():1248-1257. PubMed ID: 32755479
    [Abstract] [Full Text] [Related]

  • 8. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
    Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y.
    J Immunother Cancer; 2019 May 03; 7(1):118. PubMed ID: 31053161
    [Abstract] [Full Text] [Related]

  • 9. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma.
    Aeppli S, Eboulet EI, Eisen T, Escudier B, Fischer S, Larkin J, Gruenwald V, McDermott D, Oldenburg J, Omlin A, Porta C, Rini B, Schmidinger M, Sternberg C, Rothermundt C.
    ESMO Open; 2020 Jul 03; 5(Suppl 3):. PubMed ID: 32669298
    [Abstract] [Full Text] [Related]

  • 10. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.
    El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC.
    Crit Rev Oncol Hematol; 2017 Nov 03; 119():1-12. PubMed ID: 29065979
    [Abstract] [Full Text] [Related]

  • 11. Perspective of Oncology Patients During COVID-19 Pandemic: A Prospective Observational Study From India.
    Ghosh J, Ganguly S, Mondal D, Pandey P, Dabkara D, Biswas B.
    JCO Glob Oncol; 2020 Jun 03; 6():844-851. PubMed ID: 32552110
    [Abstract] [Full Text] [Related]

  • 12. Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?
    Pickles OJ, Lee LYW, Starkey T, Freeman-Mills L, Olsson-Brown A, Cheng V, Hughes DJ, Lee A, Purshouse K, Middleton G.
    Br J Cancer; 2020 Sep 03; 123(5):691-693. PubMed ID: 32546835
    [Abstract] [Full Text] [Related]

  • 13. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
    Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S, Voisin AL, Fain O, Mékinian A, Coutte L, Szwebel TA, Dunogeant L, Lioger B, Luxembourger C, Mariette X, Lambotte O.
    Eur J Cancer; 2017 Sep 03; 82():34-44. PubMed ID: 28646772
    [Abstract] [Full Text] [Related]

  • 14. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
    Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR.
    Ann Oncol; 2017 Oct 01; 28(10):2377-2385. PubMed ID: 28945858
    [Abstract] [Full Text] [Related]

  • 15. Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.
    Chang HL, Wei PJ, Wu KL, Huang HL, Yang CJ.
    Lung Cancer; 2020 Aug 01; 146():376-377. PubMed ID: 32576385
    [No Abstract] [Full Text] [Related]

  • 16. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
    Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, Rischin A, Frauman AG, Kee D, Smith K, Brady B, Rischin D, Gibson A, Mileshkin L, Klein O, Weickhardt A, Arulananda S, Shackleton M, McArthur G, Östör A, Cebon J, Solomon B, Buchanan RR, Wicks IP, Lo S, Hicks RJ, Sandhu S.
    Eur J Cancer; 2018 Dec 01; 105():88-102. PubMed ID: 30439628
    [Abstract] [Full Text] [Related]

  • 17. Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy.
    Bitton K, Michot JM, Barreau E, Lambotte O, Haigh O, Marabelle A, Voisin AL, Mateus C, Rémond AL, Couret C, Champiat S, Labetoulle M, Rousseau A.
    Am J Ophthalmol; 2019 Jun 01; 202():109-117. PubMed ID: 30772350
    [Abstract] [Full Text] [Related]

  • 18. Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management.
    Naidoo J, Reuss JE, Suresh K, Feller-Kopman D, Forde PM, Mehta Steinke S, Rock C, Johnson DB, Nishino M, Brahmer JR.
    J Immunother Cancer; 2020 Jun 01; 8(1):. PubMed ID: 32554619
    [Abstract] [Full Text] [Related]

  • 19. Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.
    Liew DFL, Leung JLY, Liu B, Cebon J, Frauman AG, Buchanan RRC.
    Int J Rheum Dis; 2019 Feb 01; 22(2):297-302. PubMed ID: 30549256
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
    Abou Alaiwi S, Xie W, Nassar AH, Dudani S, Martini D, Bakouny Z, Steinharter JA, Nuzzo PV, Flippot R, Martinez-Chanza N, Wei X, McGregor BA, Kaymakcalan MD, Heng DYC, Bilen MA, Choueiri TK, Harshman LC.
    J Immunother Cancer; 2020 Feb 01; 8(1):. PubMed ID: 32066646
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.